Lawrence O. Klein

2021

In 2021, Lawrence O. Klein earned a total compensation of $6M as Chief Operating Officer at CRISPR Therapeutics AG, a 63% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$273,375
Option Awards$3,618,965
Salary$450,000
Stock Awards$1,606,560
Other$11,600
Total$5,960,500

Klein received $3.6M in option awards, accounting for 61% of the total pay in 2021.

Klein also received $273.4K in non-equity incentive plan, $450K in salary, $1.6M in stock awards and $11.6K in other compensation.

Rankings

In 2021, Lawrence O. Klein's compensation ranked 2,124th out of 12,415 executives tracked by ExecPay. In other words, Klein earned more than 82.9% of executives.

ClassificationRankingPercentile
All
2,124
out of 12,415
83rd
Division
Manufacturing
821
out of 5,505
85th
Major group
Chemicals And Allied Products
315
out of 2,375
87th
Industry group
Drugs
273
out of 2,096
87th
Industry
Biological Products, Except Diagnostic Substances
84
out of 449
81st
Source: SEC filing on April 25, 2022.

Klein's colleagues

We found five more compensation records of executives who worked with Lawrence O. Klein at CRISPR Therapeutics AG in 2021.

2021

Samarth Kulkarni

CRISPR Therapeutics AG

Chief Executive Officer

2021

Brendan Smith

CRISPR Therapeutics AG

Chief Financial Officer

2021

Tony Ho

CRISPR Therapeutics AG

Former EVP, Research and Development

2021

James Kasinger

CRISPR Therapeutics AG

General Counsel

2021

Michael Tomsicek

CRISPR Therapeutics AG

Chief Financial Officer

News

In-depth

You may also like